The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use-Reference-Cited by-同舟云学术

The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use

Published:2015-05-14 Issue:5 Volume:15 Page:851-858
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Martinez-Cutillas Julio,Alerany-Pardo Carme,Borrás-Blasco Joaquín,Broto-Sumalla Antonio,Burgos-SanJosé Amparo,Climent-Bolta Consuelo,Escudero-Vilaplana Vicente,Fernández-Fuente María Anunciación,Ferrit-Martin Mónica,Gómez-Germá Pilar,Martínez-Sesmero José Manuel,Mayorga-Pérez Jesús,Menchén-Viso Belén,Merino-Alonso Javier,Polache-Vengud Josefa,Sánchez-Guerrero Amelia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737167.2015.1044514

Reference18 articles.

1. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis

2. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study

3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment;Rheumatology;2024-08-12

2. Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level;Biotechnology & Biotechnological Equipment;2022-10-19

3. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting;Expert Review of Pharmacoeconomics & Outcomes Research;2020-08-23

4. Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis;European Spine Journal;2020-05-23

5. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA;Rheumatology;2019-10-30